MedTrace Logo

An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet

NCT05462535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4785

Last updated 2022-07-18

No results posted yet for this study

Summary

This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.

During the routine medical visit, Amosartan Plus tablets were administered to patients in need of blood pressure control according to the investigator's judgment.

In this study, effectiveness and safety information of treatment of Amosartan Plus tablets was followed for 6 months (up to 12 months), and observation of the target patients was terminated after collecting relevant data.

As this study was a non-interventional observational study, all patients received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.

Conditions

  • Hypertension,Essential

Interventions

DRUG

Amosartan Plus Tab.

Amosartan Plus Tab., Once daily administered per the locally approved product information

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-26
Primary Completion
2021-07-15
Completion
2021-07-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462535 on ClinicalTrials.gov